MedTrace Logo

Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject with Lupus Nephritis

NCT04522505 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2025-01-10

No results posted yet for this study

Summary

This observation study is planned to evaluate the safety and efficacy of the subjects who received CS20AT04 in the phase 1 clinical trial.

If the subjects who participated in the phase 1 clinical trial voluntarily agree to participate in this observation study, visit 1 and visit 2 will be conducted every 3 months according to the clinical trial protocol until 6 months after administration of CS20AT04 in the phase 1 clinical trial. And Visit 3 after 6 months, Visit 4\~Visit 7 will be conducted every 12 months. During each visit, subjects are assessed for the efficacy and occurrence of adverse events.

Conditions

Sponsors & Collaborators

  • Hanyang University

    collaborator OTHER

  • Corestemchemon, Inc.

    lead INDUSTRY

Principal Investigators

  • SANG-CHEOL BAE, M.D.,Ph.D. · Hanyang University

Eligibility

Min Age
17 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-29
Primary Completion
2024-02-07
Completion
2024-07-22

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04522505 on ClinicalTrials.gov